NO821287L - Fremgangsmaate for fremstilling av et enzym (angiokinase) - Google Patents

Fremgangsmaate for fremstilling av et enzym (angiokinase)

Info

Publication number
NO821287L
NO821287L NO821287A NO821287A NO821287L NO 821287 L NO821287 L NO 821287L NO 821287 A NO821287 A NO 821287A NO 821287 A NO821287 A NO 821287A NO 821287 L NO821287 L NO 821287L
Authority
NO
Norway
Prior art keywords
angiokinase
lysate
fibrinolytic
plasminogen
stated
Prior art date
Application number
NO821287A
Other languages
English (en)
Norwegian (no)
Inventor
Gaetano Comi
Maurizio Pandolfi
Original Assignee
Manetti & Roberts Italo Brit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Manetti & Roberts Italo Brit filed Critical Manetti & Roberts Italo Brit
Publication of NO821287L publication Critical patent/NO821287L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO821287A 1981-04-23 1982-04-21 Fremgangsmaate for fremstilling av et enzym (angiokinase) NO821287L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT48332/81A IT1170913B (it) 1981-04-23 1981-04-23 Procedimento per la produzione di un principio attivo fibrinolitico vasale prodotto enzimatico specifico angiochinasi cosi' ottenuto e sue applicazioni farmaceutiche

Publications (1)

Publication Number Publication Date
NO821287L true NO821287L (no) 1982-10-25

Family

ID=11265948

Family Applications (1)

Application Number Title Priority Date Filing Date
NO821287A NO821287L (no) 1981-04-23 1982-04-21 Fremgangsmaate for fremstilling av et enzym (angiokinase)

Country Status (16)

Country Link
US (2) US4471053A (de)
EP (1) EP0064036B1 (de)
JP (1) JPS57181019A (de)
AT (1) ATE15071T1 (de)
AU (1) AU548758B2 (de)
CA (1) CA1184138A (de)
DE (1) DE3265559D1 (de)
DK (1) DK180682A (de)
ES (1) ES8501797A1 (de)
IE (1) IE53107B1 (de)
IL (1) IL65448A (de)
IT (1) IT1170913B (de)
NO (1) NO821287L (de)
NZ (1) NZ200254A (de)
PT (1) PT74743B (de)
ZA (1) ZA822703B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA831399B (en) * 1982-03-05 1984-02-29 Health Lab Service Board New fibrinolytic enzymes and methods for their production and pharmaceutical compositions containing them
JPS58189122A (ja) * 1982-04-30 1983-11-04 Kaken Pharmaceut Co Ltd 高脂血症予防治療剤
JPS61112018A (ja) * 1984-11-06 1986-05-30 Mitsubishi Chem Ind Ltd 線溶増強剤
US5165938A (en) * 1984-11-29 1992-11-24 Regents Of The University Of Minnesota Wound healing agents derived from platelets
US5275812A (en) * 1985-06-07 1994-01-04 The General Hospital Corporation Method of treatment for myocardial infarction
US5032608A (en) * 1986-09-10 1991-07-16 Dudrick Stanley J Method and substrate composition for treating atherosclerosis
US5248688A (en) * 1986-09-10 1993-09-28 Dudrick Medical Research Fund I, Ltd. Method and substrate composition for treating atherosclerosis
HU209955B (en) * 1987-07-01 1994-12-28 Genentech Inc Process for producing pharmaceutical compositions containing tissue- -plasminogen-activator of poor solubility for inhibiting production and regeneration of deformities
US5215908A (en) * 1989-06-13 1993-06-01 Genencor International, Inc. Process for recovery and purification of chymosin
US5449679A (en) * 1994-07-29 1995-09-12 Leonard; Robert J. Process and products for reducing biological fluid levels of a lipid soluble waste
US20080199513A1 (en) * 1997-06-24 2008-08-21 Cascade Medical Enterprises, Llc Systems and methods for preparing autologous fibrin glue
US7745106B2 (en) * 1997-06-24 2010-06-29 Cascade Medical Enterprises, Llc Methods and devices for separating liquid components
US6979307B2 (en) * 1997-06-24 2005-12-27 Cascade Medical Enterprises Llc Systems and methods for preparing autologous fibrin glue
MXPA00000009A (es) 1998-06-22 2005-09-08 Autologous Wound Therapy Inc Solicitud para patente de utilidad para curativo de heridas mejorado enriquecido con plaquetas.
EP1890820A4 (de) * 2005-03-22 2012-04-11 Cascade Medical Entpr Llc Systeme und verfahren zur herstellung von membranen
DE102015010436B4 (de) * 2015-08-14 2019-01-24 Airbus Defence and Space GmbH Wabenkern für dimensionsstabile Sandwichbauteile, dessen Verwendung, Sandwichplatte mit diesem Wabenkern und Verfahren zur Herstellung des Wabenkerns

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998847A (en) * 1972-10-25 1976-12-21 Schering Aktiengesellschaft 9,10-secoestrane derivatives and their production
US3998947A (en) * 1973-11-30 1976-12-21 Pierre Fabre S.A. Process for obtaining a plasminogen activator
US4245051A (en) * 1978-03-30 1981-01-13 Rockefeller University Human serum plasminogen activator
NZ191320A (en) * 1978-09-07 1982-09-14 Beecham Group Ltd In vivo fibrinolytic enzyme having active site blocked by hydrolytically removable group pharmaceutical compositions
US4374830A (en) * 1979-10-04 1983-02-22 Research Corp. Platelet aggregating material from equine arterial tissue
US4381346A (en) * 1979-11-13 1983-04-26 Huasin Syed S Isolation of plasminogen activators useful as therapeutic and diagnostic agents
US4390630A (en) * 1980-10-28 1983-06-28 The Regents Of The University Of California Hementin--a fibrinolytic agent

Also Published As

Publication number Publication date
JPS57181019A (en) 1982-11-08
EP0064036B1 (de) 1985-08-21
IE820952L (en) 1982-10-23
NZ200254A (en) 1985-07-12
ATE15071T1 (de) 1985-09-15
IT8148332A0 (it) 1981-04-23
DE3265559D1 (en) 1985-09-26
PT74743B (en) 1983-11-09
IL65448A0 (en) 1982-07-30
ES511604A0 (es) 1984-12-01
AU548758B2 (en) 1986-01-02
ES8501797A1 (es) 1984-12-01
IT8148332A1 (it) 1982-10-23
PT74743A (en) 1982-05-01
CA1184138A (en) 1985-03-19
ZA822703B (en) 1983-03-30
AU8237582A (en) 1982-10-28
EP0064036A1 (de) 1982-11-03
US4471053A (en) 1984-09-11
DK180682A (da) 1982-10-24
IE53107B1 (en) 1988-06-22
US4532129A (en) 1985-07-30
IT1170913B (it) 1987-06-03
IL65448A (en) 1985-07-31

Similar Documents

Publication Publication Date Title
NO821287L (no) Fremgangsmaate for fremstilling av et enzym (angiokinase)
Andrade-Gordon et al. Interaction of heparin with plasminogen activators and plasminogen: effects on the activation of plasminogen
Rijken et al. Relationship between tissue plasminogen activator and the activators in blood and vascular wall
Fletcher et al. The maintenance of a sustained thrombolytic state in man. I. Induction and effects
AU596951B2 (en) Blood coagulation inhibiting proteins, processes for preparing them and their uses
CN108472342A (zh) 一种用于预防或治疗急性及慢性血栓的方法
Ryle Parapepsinogen II: the zymogen of parapepsin II
Shafer et al. Monitoring activity of fibrinolytic agents: a therapeutic challenge
Schulman Studies on the medical treatment of deep vein thrombosis
Tollefsen et al. Modulation of heparin cofactor II activity by histidine-rich glycoprotein and platelet factor 4.
Andersen et al. Fibrinolytic and fibrin stabilizing activity of synovial membranes
Spanier et al. Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog
US4780412A (en) Fibrinolytic enzymes produced from established non-cancerous cell lines
Pandolfi et al. Partial purification and characterization of keratokinase, the fibrinolytic activator of the cornea
Tomikawa et al. Experimental model of pulmonary thrombosis in rat
Moore et al. Peritoneal fibrinolysis: evidence for the efficiency of the tissue-type plasminogen activator
Silberman et al. Effects of ancrod (Arvin) in mice: studies of plasma fibrinogen and fibrinolytic activity
US5977056A (en) Treatment of thrombotic events
Hong et al. Lipoprotein (a) levels and fibrinolytic activity in patients with nephrotic syndrome
Turpie et al. In‐vitro studies with ancrod (‘Arvin’)
Kierulf et al. Fibrinaemia and Multiple Thrombi in Pancreatic Carcinoma: A Case Studied with Quantitative N‐Terminal Analysis
Kok et al. Differentiation between plasminogen activators by means of epsilon-aminocaproic acid
NO166314B (no) Fremgangsmaate for fremstilling av en plasminogenaktivatoravledet fra human nyre.
US3509024A (en) Aspergillopeptidase for use in therapy and a process for the preparation thereof
Amris et al. Infusion of porcine plasmin in man. Studies on toxicology and pharmacodynamics